Cargando…
Using machine learning and big data to explore the drug resistance landscape in HIV
Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are commonly transmitted to naive patients. The standard approach to reveal new DRMs is to test for significant frequency differences of mutations between treated and naive patients. However, we then consider each mutation...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425536/ https://www.ncbi.nlm.nih.gov/pubmed/34437532 http://dx.doi.org/10.1371/journal.pcbi.1008873 |
_version_ | 1783749865664151552 |
---|---|
author | Blassel, Luc Tostevin, Anna Villabona-Arenas, Christian Julian Peeters, Martine Hué, Stéphane Gascuel, Olivier |
author_facet | Blassel, Luc Tostevin, Anna Villabona-Arenas, Christian Julian Peeters, Martine Hué, Stéphane Gascuel, Olivier |
author_sort | Blassel, Luc |
collection | PubMed |
description | Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are commonly transmitted to naive patients. The standard approach to reveal new DRMs is to test for significant frequency differences of mutations between treated and naive patients. However, we then consider each mutation individually and cannot hope to study interactions between several mutations. Here, we aim to leverage the ever-growing quantity of high-quality sequence data and machine learning methods to study such interactions (i.e. epistasis), as well as try to find new DRMs. We trained classifiers to discriminate between Reverse Transcriptase Inhibitor (RTI)-experienced and RTI-naive samples on a large HIV-1 reverse transcriptase (RT) sequence dataset from the UK (n ≈ 55, 000), using all observed mutations as binary representation features. To assess the robustness of our findings, our classifiers were evaluated on independent data sets, both from the UK and Africa. Important representation features for each classifier were then extracted as potential DRMs. To find novel DRMs, we repeated this process by removing either features or samples associated to known DRMs. When keeping all known resistance signal, we detected sufficiently prevalent known DRMs, thus validating the approach. When removing features corresponding to known DRMs, our classifiers retained some prediction accuracy, and six new mutations significantly associated with resistance were identified. These six mutations have a low genetic barrier, are correlated to known DRMs, and are spatially close to either the RT active site or the regulatory binding pocket. When removing both known DRM features and sequences containing at least one known DRM, our classifiers lose all prediction accuracy. These results likely indicate that all mutations directly conferring resistance have been found, and that our newly discovered DRMs are accessory or compensatory mutations. Moreover, apart from the accessory nature of the relationships we found, we did not find any significant signal of further, more subtle epistasis combining several mutations which individually do not seem to confer any resistance. |
format | Online Article Text |
id | pubmed-8425536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84255362021-09-09 Using machine learning and big data to explore the drug resistance landscape in HIV Blassel, Luc Tostevin, Anna Villabona-Arenas, Christian Julian Peeters, Martine Hué, Stéphane Gascuel, Olivier PLoS Comput Biol Research Article Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are commonly transmitted to naive patients. The standard approach to reveal new DRMs is to test for significant frequency differences of mutations between treated and naive patients. However, we then consider each mutation individually and cannot hope to study interactions between several mutations. Here, we aim to leverage the ever-growing quantity of high-quality sequence data and machine learning methods to study such interactions (i.e. epistasis), as well as try to find new DRMs. We trained classifiers to discriminate between Reverse Transcriptase Inhibitor (RTI)-experienced and RTI-naive samples on a large HIV-1 reverse transcriptase (RT) sequence dataset from the UK (n ≈ 55, 000), using all observed mutations as binary representation features. To assess the robustness of our findings, our classifiers were evaluated on independent data sets, both from the UK and Africa. Important representation features for each classifier were then extracted as potential DRMs. To find novel DRMs, we repeated this process by removing either features or samples associated to known DRMs. When keeping all known resistance signal, we detected sufficiently prevalent known DRMs, thus validating the approach. When removing features corresponding to known DRMs, our classifiers retained some prediction accuracy, and six new mutations significantly associated with resistance were identified. These six mutations have a low genetic barrier, are correlated to known DRMs, and are spatially close to either the RT active site or the regulatory binding pocket. When removing both known DRM features and sequences containing at least one known DRM, our classifiers lose all prediction accuracy. These results likely indicate that all mutations directly conferring resistance have been found, and that our newly discovered DRMs are accessory or compensatory mutations. Moreover, apart from the accessory nature of the relationships we found, we did not find any significant signal of further, more subtle epistasis combining several mutations which individually do not seem to confer any resistance. Public Library of Science 2021-08-26 /pmc/articles/PMC8425536/ /pubmed/34437532 http://dx.doi.org/10.1371/journal.pcbi.1008873 Text en © 2021 Blassel et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Blassel, Luc Tostevin, Anna Villabona-Arenas, Christian Julian Peeters, Martine Hué, Stéphane Gascuel, Olivier Using machine learning and big data to explore the drug resistance landscape in HIV |
title | Using machine learning and big data to explore the drug resistance landscape in HIV |
title_full | Using machine learning and big data to explore the drug resistance landscape in HIV |
title_fullStr | Using machine learning and big data to explore the drug resistance landscape in HIV |
title_full_unstemmed | Using machine learning and big data to explore the drug resistance landscape in HIV |
title_short | Using machine learning and big data to explore the drug resistance landscape in HIV |
title_sort | using machine learning and big data to explore the drug resistance landscape in hiv |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425536/ https://www.ncbi.nlm.nih.gov/pubmed/34437532 http://dx.doi.org/10.1371/journal.pcbi.1008873 |
work_keys_str_mv | AT blasselluc usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv AT tostevinanna usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv AT villabonaarenaschristianjulian usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv AT peetersmartine usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv AT huestephane usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv AT gascuelolivier usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv AT usingmachinelearningandbigdatatoexplorethedrugresistancelandscapeinhiv |